ABSTRACT
BACKGROUND: This study aimed to investigate the effects of prone position ventilation treatment on patients with acute respiratory distress syndrome (ARDS) after cardiac surgery. METHODS: Clinical data were collected from 93 hospitalized patients with acute respiratory distress syndrome (ARDS) in the intensive care unit (ICU) of cardiology from February 2021 to February 2023. Patients were divided into supine position group (n = 45) and prone position group (n = 48). The difference in 28-days survival rates, blood gas indicators, respiratory mechanics indicators, and adverse events before and after treatment was analyzed. RESULTS: We found that within 28 days of admission, 8.33% of ARDS patients in prone position group and 11.11% in supine position group died of all causes (p > .05). After treatment, the levels of arterial PaO2 (103.25 ± 9.44 in prone position group and 91.62 ± 9.18 in supine position group), PaCO2 (30.26 ± 5.54 and 36.56 ± 6.37), blood LAC (1.35 ± 0.37 and 1.68 ± 0.42), oxygenation (232.23 ± 28.56 and 205.13 ± 31.34) and diffusion index (453.48 ± 63.30 and 395.18 ± 58.54) in both groups were improved (p < .001). Moreover, the increase in prone position group was more remarkable. After treatment, the respiratory mechanics indexes of the lung compliance as well as respiratory resistance were improved (p < .05). Moreover, the increase in supine position group was more remarkable (p < .05). The incidence of atelectasis in prone position group was lower than that in supine position group (p < .05). Additionally, the alteration in other adverse events showed no significant difference between the two groups (p > .05). CONCLUSIONS: Taken together, prone position ventilation in patients with ARDS after cardiac surgery improved blood gas indexes, hypoxemia, and respiratory mechanics indexes, as well as reduced the incidence of atelectasis.
ABSTRACT
INTRODUCTION: There were controversial opinions on the use of bivalirudin versus heparin for anticoagulant therapy in extracorporeal membrane oxygenation. The aim of our present study is to evaluate the efficacy and safety of bivalirudin versus heparin for the maintenance of systemic anticoagulation during adult veno-venous extracorporeal membrane oxygenation (V-V ECMO). METHODS: Adult patients who received V-V ECMO support in our center between February 2018and February 2022 were retrospectively recruited. We analyzed their ECMO support time, platelet count, coagulation indicators, blood product infusion volume, the incidence of thrombosis and bleeding, probability of successful weaning of ECMO, and in-hospital mortality. RESULTS: A total of 58 patients received V-V ECMO support. Thirty-four patients were finally included according to the exclusion and inclusion criteria, 14 and 20 accepted bivalirudin and heparin for anticoagulant therapy, respectively. The Minimum platelet value (98.50 × 109/L (85.50, 123.75) vs 49.50 × 109/L (31.25, 83.00), p = 0.002) and mean platelet value (149.90 × 109/L (127.40, 164.80) vs 74.55 × 109/L (62.45, 131.60), p = 0.03) and the ratio of successful weaning of ECMO (92.8% vs 60.0%, p = 0.033) in bivalirudin group were significantly higher than those in heparin group. The red blood cell infusion volume (7.00 U (3.00, 13.25) vs 13.75 U (7.25, 22.63), p = 0.039), platelet infusion volume (0.00 mL (0.00, 75.00) vs 300 mL (0.00, 825.00), p = 0.027), and the incidence of major bleeding (0.00% vs 30%, p = 0.024) in bivalirudin group were significantly lower than those in heparin group. CONCLUSIONS: In V-V ECMO-supported adult patients, systemic anticoagulation with bivalirudin has achieved the same anticoagulation targets as heparin with less frequency of major bleeding events and lower requirement for blood products without significantly increased risk of thrombosis. Bivalirudin most likely is a safe and effective anticoagulation method for adult patients supported by V-V ECMO.